Pipeline
March Biosciences is dedicated to revolutionizing patient care by discovering and exploiting high-impact targets for cancer immunotherapy. Our lead asset, MB-105, is designed to treat relapse/refractory T-cell malignancies, currently with no effective and curative alternative treatments
CAR-T Therapy
1. Collection of T cells:
2. Genetic modification of T cells:
3. Expansion and activation of CAR T cells:
4. Infusion of CAR T cells:
Following expansion and activation CAR-T cells are then infused back into the patient’s bloodstream intravenously.
This, allow CAR-T cells to circulate and recognize cancer cells expressing the target antigen.
Ongoing trial
Our lead asset, MB-105 is currently being evaluated in a Phase 1 clinical trial (NCT03081910) for T-cell lymphoma and T-cell acute lymphoblastic leukemia (TCL and T-ALL). Initial results have revealed promising signals of safety and efficacy for these patients, who otherwise have limited treatment options. Enrollment for this trial is ongoing.
News & Publications
Read more about how March Biosciences’ research has impacted the medical community.